Edition:
United States

Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

12.41USD
26 May 2017
Change (% chg)

$-0.19 (-1.51%)
Prev Close
$12.60
Open
$12.52
Day's High
$12.64
Day's Low
$12.36
Volume
213,117
Avg. Vol
377,254
52-wk High
$15.19
52-wk Low
$7.71

HALO.OQ

Chart for HALO.OQ

About

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex... (more)

Overall

Beta: 2.26
Market Cap(Mil.): $1,611.31
Shares Outstanding(Mil.): 129.84
Dividend: --
Yield (%): --

Financials

  HALO.OQ Industry Sector
P/E (TTM): -- 137.90 17.41
EPS (TTM): -0.91 -- --
ROI: -56.65 -8.48 -5.42
ROE: -- -11.31 -4.68

BRIEF-Halozyme Therapeutics prices public offering of common stock

* Halozyme Therapeutics prices public offering of common stock

May 18 2017

BRIEF-Halozyme Therapeutics announces public offering of common stock

* Halozyme Therapeutics announces public offering of common stock

May 18 2017

BRIEF-Halozyme's PEGPH20 increases immune response, effectiveness of immunotherapies in preclinical cancer models

* Halozyme's PEGPH20 increases immune response and effectiveness of immunotherapies in preclinical cancer models

Apr 03 2017

BRIEF-Halozyme provides update on SWOG Collaborative Group clinical study

* Halozyme provides update on swog collaborative group clinical study

Mar 30 2017

BRIEF-Halozyme Therapeutics Q4 loss per share $0.21

* Says for 2017, company reiterated and updated cash portions of its financial guidance

Feb 28 2017

BRIEF-First Eagle Investment Management LLC reports a 5.94 pct passive stake in Halozyme Therapeutics as of Dec 31 - SEC Filing

* First Eagle Investment Management LLC reports a 5.94 percent passive stake in Halozyme Therapeutics Inc as of December 31, 2016 - SEC Filing Source text: [http://bit.ly/2kkBxab] Further company coverage:

Feb 06 2017

BRIEF-Halozyme Therapeutics sees FY 2017 revenue $115 mln to $130 mln

* Halozyme Therapeutics-expects to report $20 million in 2016 revenue for reimbursed partner research and development expenses

Jan 09 2017

BRIEF-Halozyme sees FY 2017 revenue $115 mln to $130 mln

* Halozyme provides program updates, 2017 financial guidance at 35th annual JP Morgan healthcare conference

Jan 09 2017

Halozyme's pancreatic cancer drug succeeds in mid-stage trial

Halozyme Therapeutics Inc said its lead experimental drug, in tandem with therapies from Celgene Corp and Eli Lilly and Co, succeeded in a mid-stage study involving patients with an advanced form of pancreatic cancer.

Jan 05 2017

More From Around the Web

Competitors

Earnings vs. Estimates